YOJEMTU
LIVE

Serial Number

79422222

Owner

Synox Therapeutics UK Limited

Attorney

Andrea L Calvaruso

Filing Date

Mar 4, 2025

Add to watchlist:

No watchlists yet
View on USPTO

YOJEMTU Trademark

Serial Number: 79422222 • Registration: 8090756

YOJEMTU is a trademark filed by Synox Therapeutics UK Limited on March 4, 2025. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Synox Therapeutics UK Limited (2 trademarks)

John Eccles House,

Entity Type: 98

Trademark Details

Filing Date

March 4, 2025

Registration Date

January 6, 2026

Published for Opposition

November 18, 2025

Goods & Services

Pharmaceutical and biological preparations for the treatment of cancer and non-cancer fibrotic and inflammatory diseases for medical purposes; monoclonal antibodies for medical use; pharmaceutical preparations for the prevention, diagnosis and treatment of cancer and immune-mediated inflammatory and autoimmune diseases, namely tenosynovial giant cell tumor (TGCT), graft-versus-host disease, acute myeloid leukemia, chronic myelomonocytic leukemia, soft-tissue sarcoma, ovarian cancer, triple-negative breast cancer, head and neck cancer, malignant meningioma, T-cell lymphoma, osteosarcoma, glioblastoma, follicular lymphoma and malignant pleural mesothelioma; diagnostic reagents for medical purposes for use in connection with tenosynovial giant cell tumor (TGCT), graft-versus-host disease, acute myeloid leukemia, chronic myelomonocytic leukemia, soft tissue sarcoma, ovarian cancer, triple-negative breast cancer, head and neck cancer, malignant meningioma, T-cell lymphoma, osteosarcoma, glioblastoma, follicular lymphoma and malignant pleural mesothelioma

Scientific and medical research; pharmaceutical research and development; drug discovery services; pharmaceutical product development; testing of pharmaceuticals; medical and scientific research, namely, conducting clinical trials for others; clinical scientific research in the fields of oncology and immunology; providing medical and scientific research information in the fields of oncology and immunology; design and development of pharmaceutical preparations and medicines

Filing History

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Apr 6, 2026 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jan 6, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Jan 6, 2026 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 18, 2025 NPUB
PUBLISHED FOR OPPOSITION
Nov 18, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 12, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 16, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Oct 16, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Oct 16, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Oct 16, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Oct 16, 2025 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 14, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 9, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 9, 2025 TROA
REFUSAL PROCESSED BY IB
Oct 3, 2025 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sep 17, 2025 RFCS
REFUSAL PROCESSED BY MPU
Sep 16, 2025 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Aug 7, 2025 RFCR
NON-FINAL ACTION WRITTEN
Aug 6, 2025 CNRT
ASSIGNED TO EXAMINER
Aug 5, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
Apr 28, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 28, 2025 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Apr 24, 2025 REPR